Russell Microcap Index

Quipt Home Medical on Preliminary List to Join Russell Microcap® Index

Retrieved on: 
Monday, June 6, 2022
Internet, Human, Russell Microcap Index, Company, FTSE Russell, Insurance, ETF, TSX Venture Exchange, Sleep, Legislation, CEO, Conditional sentence, Environment, Fraud, Method, Growth, GLOBE, Patient, Crime, Technology, Risk, NASDAQ, Attack, Heart, Disease management, Russell, Index, Industrial design, Nasdaq

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (Quipt or the Company) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce it is on a preliminary list dated June 3, 2022 issued by the Russell Microcap Index to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022.

Key Points: 
  • CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (Quipt or the Company) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce it is on a preliminary list dated June 3, 2022 issued by the Russell Microcap Index to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022.
  • Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the Russell Reconstitution section on the FTSE Russell website .
  • While the Company is on the June 3, 2022 preliminary list for inclusion on the Russell Microcap Index, no assurance can be given that it will ultimately on the final list.

180 Degree Capital Corp. Provides Updates on Potential $6.8 Million Petra Milestone Payment and Other Business Developments

Retrieved on: 
Thursday, January 27, 2022
U.S. Securities and Exchange Commission, TARA, Eli Lilly and Company, Program, D-Wave Systems, History, SMA, Risk, Russell Microcap Index, Capital, NASDAQ, Asset, Security (finance), Fed, Achievement, NAV, Petra, Weakness, GLOBE, Acquisition, Greenbriar Capital Corp, Bank, Lilly

Although 180 cannot assure our investors when such an event may occur, if at all, such an event would trigger a contractual payment to former Petra shareholders, including 180.

Key Points: 
  • Although 180 cannot assure our investors when such an event may occur, if at all, such an event would trigger a contractual payment to former Petra shareholders, including 180.
  • The $6.8 million payment, if received, would increase cash per share by $0.66, or 9% of our closing price on January 26, 2022.
  • Should that milestone be achieved, 180 would receive an additional approximately $5.5 million.
  • If you add the potential Petra milestone payment of $0.66 per share to our end-of-year Public Focused Assets, our pro forma Public Focused Assets would be over $8.00.

Westwater Resources Provides Year-End 2021 Review and Update on Coosa Graphite Processing Plant

Retrieved on: 
Wednesday, January 12, 2022
Mining, Minerals, Natural Resources, Mineral, Board, Technology, News, Forward-looking statement, Engineering, Facility, Overalls, Government, Private Securities Litigation Reform Act, Intention, DFS, COVID-19, Board of directors, NYSE American, Letter, NYSE, Graphite, CEO, CSPG, Russell Microcap Index, Samuel, Â, Industry, Goal, Controller, Program, Company, Westwater, Sale, Patent, Unitary state, United States patent law, Laboratory, Partnership, Vanadium, Uranium, Construction, Aluminium

Westwater Resources, Inc. (NYSE American: WWR), a battery grade, graphite development company (Westwater or Company), today provided a business update.

Key Points: 
  • Westwater Resources, Inc. (NYSE American: WWR), a battery grade, graphite development company (Westwater or Company), today provided a business update.
  • In October 2021, Westwater completed the Definitive Feasibility Study (DFS) for its Coosa Graphite Production Facility (the Facility) to be located near Kellyton, Alabama.
  • On October 11, 2021, Westwater announced that its Board of Directors approved the purchase of two buildings adjacent to the plant .
  • Also, in 2021 Westwater completed the production of 13.2 mt of purified graphite from the pilot program for performance testing.

Femasys Inc. To Join the Russell Microcap® Index

Retrieved on: 
Monday, September 20, 2021
IOSCO, Tubing (recreation), FTSE Russell, Health, Risk, Security (finance), NASDAQ, U.S. Securities and Exchange Commission, Russell Microcap Index, Infertility, ETF, CPSS-IOSCO Principles for Financial Market Infrastructures, Russell, Company, Woman, Growth, London Stock Exchange Group, Technology, IPO, Forward-looking statement, Safety, Index, SEC, GLOBE, Oil, Industrial design, Birth control

The Russell MicrocapIndex is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Key Points: 
  • The Russell MicrocapIndex is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, please visit www.ftserussell.com .

Miromatrix Medical Added to Russell Microcap® Index

Retrieved on: 
Monday, September 20, 2021
AUM, Russell Microcap Index, FTSE Russell, NASDAQ, FDA, MIRO, Russell, Company, Technology, IND, EDEN, GLOBE, 3D printing, Life insurance

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will be added to the Russell Microcap Index, effective after the U.S. market opens today, September 20, 2021.

Key Points: 
  • EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will be added to the Russell Microcap Index, effective after the U.S. market opens today, September 20, 2021.
  • The Russell Microcap Index measures the microcap segment of the U.S. equity market, consisting of the smallest 1,000 securities in the small-cap Russell 2000 Index, plus the next 1,000 smallest eligible securities by market cap.
  • "We are honored and thrilled to be a part of the Russell Microcap Index, and we believe the inclusion will increase our visibility and exposure with investors," said Jeff Ross, Ph.D., Miromatrix CEO.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website .

Richardson Electronics Selects SM Berger & Company, Inc. to Lead Strategic Investor Relations Program

Retrieved on: 
Tuesday, September 14, 2021
Russell Microcap Index, Health, U.S. Securities and Exchange Commission, CT, Income, Security (finance), RF, Form 10-K, Engineering, System, Nasdaq, Aviation, MRI, Company, SM, Securities Act of 1933, Electronics, Annual report, Google Images, NASDAQ, Solution, GLOBE, Mobile phone

Founded in 1984, SM Berger & Company has partnered with over 100 companies to develop and manage modern, integrated, and results-oriented investor relations and communications programs.

Key Points: 
  • Founded in 1984, SM Berger & Company has partnered with over 100 companies to develop and manage modern, integrated, and results-oriented investor relations and communications programs.
  • SM Berger & Company specializes in helping underfollowed small- and micro-cap companies across multiple industries engage with the capital markets.
  • SM Berger will oversee Richardson Electronics investor relations functions and serve as a key point of contact for shareholders.
  • About SM Berger & Company, Inc.
    As one of the nations oldest investor relations firms, SM Berger & Company, Inc. has helped over 100 small- and micro-cap companies develop and manage their investor relations programs, improve their communications, and increase their investor following.

iSpecimen Announces Inclusion in Russell Microcap® Index

Retrieved on: 
Tuesday, September 14, 2021
Russell Microcap Index, Russell, U.S. Securities and Exchange Commission, Security (finance), CEO, Forward-looking statement, Index, CPSS-IOSCO Principles for Financial Market Infrastructures, Securities Exchange Act of 1934, Doctor of Philosophy, Patient, Company, Securities Act of 1933, ETF, FTSE Russell, MD, Growth, Review, London Stock Exchange Group, The Company, Hospital, Organization, IOSCO, Industrial design

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Key Points: 
  • Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • "Our inclusion to the Russell Microcap Index is an important milestone and reflects iSpecimen's efforts and growth as we continue to streamline the biospecimen procurement process.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website .

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Retrieved on: 
Monday, September 13, 2021
Russell Microcap Index, Program, QIDP, Absorption, HERE, Traction, CEO, Private Securities Litigation Reform Act, FDA, IPO, Minimum inhibitory concentration, Hand, Marketing, Patient, Infection, SMMT, Colon, Acrux, Ridinilazole, LLC, Optimism, Risk, Clinical trial, Kepler-86, Advertising, Daptomycin, Congress, NASDAQ, Stock dilution, Review, MIC, Death, Recurrence, Fast track (FDA), Goal, SEC, Research, HPM, Phase 3, Fine chemical, Risk management, Pharmaceutical industry, Antibiotics, Dietary supplement, Security (finance)

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Retrieved on: 
Monday, September 13, 2021
Russell Microcap Index, Program, QIDP, Absorption, HERE, Traction, CEO, Private Securities Litigation Reform Act, FDA, IPO, Minimum inhibitory concentration, Hand, Marketing, Patient, Infection, SMMT, Colon, Acrux, Ridinilazole, LLC, Optimism, Risk, Clinical trial, Kepler-86, Advertising, Daptomycin, Congress, NASDAQ, Stock dilution, Review, MIC, Death, Recurrence, Fast track (FDA), Goal, SEC, Research, HPM, Phase 3, Fine chemical, Risk management, Pharmaceutical industry, Antibiotics, Dietary supplement, Security (finance)

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results

Retrieved on: 
Tuesday, August 17, 2021
Transfer, Company, STARS, Private Securities Litigation Reform Act, University, Gold, Growth, Therapy, Cancer, U.S. Securities and Exchange Commission, Protein, Orphan drug, GLOBE, Intention, Security (finance), Russell, University of Louisville School of Medicine, Research, DNA, Nasdaq, RAS, Time, Senior, Risk, Treatment of lung cancer, MBA, Clinical trial, Russell Microcap Index, Form 10-K, IND, Safety, News, Patient, FTSE Russell, Patent, Toxicity, ALAN, Acute myeloid leukemia, Pancreatic cancer, FDA, COVID-19, Technology, MD, Pharmaceutical industry, Animal, Online gambling, Cryptocurrency, Life insurance

Qualigen also today announces its second quarter and six-months 2021 financial results and provides a recap of the highlights of the 2021 second quarter.

Key Points: 
  • Qualigen also today announces its second quarter and six-months 2021 financial results and provides a recap of the highlights of the 2021 second quarter.
  • Orphan Drug status, if obtained, would be expected to confer several advantages including faster review and increased market protection.
  • In May 2021, Qualigen announced that it had named Tariq Arshad, MD, MBA, to the newly-created position of Senior Vice President, Chief Medical Officer.
  • Revenues for the six month period ended June 30, 2021 were $3.0 million compared to $2.4 million in the same six month period of the previous year.